FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) [2014] FCAFC 126
Citation: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) [2014] FCAFC 126 Appeal from: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) [2011] FCA 846 Parties: APOTEX PTY LTD (ACN 096 916 148) v SANOFI-AVENTIS AUSTRALIA PTY LTD
(ACN 008 558 807), SANOFI-AVENTIS DEUTSCHLAND GMBH and AVENTISUB II INCORPORATEDFile number(s): NSD 2133 of 2011 Judge(s): BENNETT AND YATES JJ Date of judgment: 26 September 2014 Catchwords: COSTS – respondents successful at first instance and before the Full Court – appellant successful on infringement before the High Court – whether costs should follow the event or be assessed on an issues basis – percentage reduction of entitlement to costs Legislation: Australian Consumer Law 2011 (Cth), s 18
Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth)
Trade Practices Act 1974 (Cth), s 52Cases cited: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50
DSI Australia (Holdings) Pty Ltd v Garford Pty Ltd [2013] FCA 268
H Lundbeck A/S v Alphapharm Pty Ltd (No 2) [2009] FCAFC 118
PAC Mining Pty Ltd v Esco Corporation (No 2) [2009] FCAFC 52Date of hearing: On the papers Date of last submissions: 6 March 2014 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 32 Counsel for the Appellant: D Catterns QC and N Murray Solicitor for the Appellant: Herbert Smith Freehills Counsel for the Respondents: R Cobden SC and C Dimitriadis Solicitor for the Respondents: Jones Day
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 2133 of 2011
ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN: APOTEX PTY LTD ACN 096 916 148
AppellantAND: SANOFI-AVENTIS AUSTRALIA PTY LTD
ACN 008 558 807
Respondent
JUDGES:
BENNETT AND YATES JJ
DATE OF ORDER:
26 SEPTEMBER 2014
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The respondents pay 60% of the appellant’s costs of the patent case at first instance.
2.The appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011.
3.The respondents pay 70% of the appellant’s costs of the appeal.
4.The matter be remitted to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 2133 of 2011
ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN: APOTEX PTY LTD ACN 096 916 148
AppellantAND: SANOFI-AVENTIS AUSTRALIA PTY LTD
ACN 008 558 807
Respondent
JUDGES:
BENNETT AND YATES JJ
DATE:
26 SEPTEMBER 2014
PLACE:
SYDNEY
REASONS FOR JUDGMENT
After determination in the High Court (Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] FCAFC 126
- Decision Date
CaseChat Overview and Summary
The court considered the factors relevant to the broad discretion to award costs under section 43 of the Federal Court of Australia Act 1976 (Cth) in complex patent litigation such as this. The court noted that it was not uncommon for a party to cross-claim for revocation of a patent, but that such a claim may have costs consequences. The court distinguished between assertions of lack of novelty and obviousness, which could be considered discrete issues, and lack of fair basis, which may be ‘wrapped up’ in the arguments on construction. The court took into account that Apotex was ultimately successful in defending patent infringement but that its attack on the patent validity failed; Sanofi was successful in upholding patent validity in the face of the attack pressed in the appeal. Sanofi was successful in the copyright infringement case but that occupied a relatively small part of the appeal. The court considered that it was appropriate to make orders for the costs of the appeal compendiously, that is, of the patent case on infringement, the patent case on validity and the copyright infringement case.
Sanofi maintained its right to a separate order for the costs of the copyright claim but, in the alternative, set out its basis for apportionment. It submitted that any award of costs to Apotex for the appeal should be reduced by around 30%, to reflect the time taken for arguments on which Apotex failed. As to the trial, Sanofi submitted that a reduction of the order of 80% would be appropriate, but that this question should be remitted to the primary judge for determination. Sanofi pointed out that the time spent at trial was not all attributable to the patent case and said that the copyright case, on which it was successful, occupied at least 40% of the hearing time at trial and well in excess of 5% of the appeal. The court accepted Sanofi’s submissions and made orders for costs accordingly.
The court ordered that the respondents pay 60% of the appellant’s costs of the patent case at first instance. The court ordered that the appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011. The court ordered that the respondents pay 70% of the appellant’s costs of the appeal. The court remitted the matter to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.
Orders
Orders of the court
1. The respondents pay 60% of the appellant’s costs of the patent case at first instance.
2. The appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011.
3. The respondents pay 70% of the appellant’s costs of the appeal.
4. The matter be remitted to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Sanofi maintains its right to a separate order for the costs of the copyright claim but, in the alternative, sets out its basis for apportionment. It submits that any award of costs to Apotex for the appeal should be reduced by around 30%, to reflect the time taken for arguments on which Apotex failed. As to the trial, Sanofi submits that a reduction of the order of 80% would be appropriate, but that this question should be remitted to the primary judge for determination. Sanofi points out that the time spent at trial was not all attributable to the patent case and says that the copyright case, on which it was successful, occupied at least 40% of the hearing time at trial and well in excess of 5% of the appeal. CONSIDERATION The factors relevant to the broad discretion to award costs under s 43 of the Federal Court of Australia Act 1976 (Cth) in complex patent litigation such as this have been referred to and summarised, for example, in PAC, H Lundbeck A/S v Alphapharm Pty Ltd (No 2) [2009] FCAFC 118 (Lundbeck) and DSI Australia (Holdings) Pty Ltd v Garford Pty Ltd [2013] FCA 268 (DSI). . Apotex says that the invalidity claim should be treated as a defensive claim against infringement. It is, of course, not uncommon for an allegedly infringing party to cross-claim for revocation. However, as explained in PAC, that may have costs consequences. In PAC, the Full Court discussed the competing factors where a party was successful in defending infringement but unsuccessful in a cross-claim for revocation of the patent. As their Honours said at [11], and is the case here, the respondent to the infringement action (here Apotex), could have successfully defended infringement without putting validity in issue. The claim for revocation was, their Honours observed, more than the presentation of conventional alternative defences to infringement, it was also a challenge to the validity of the patent. An unsuccessful attack entitled the patentee (here Sanofi), to obtain a certificate of validity. Their Honours were of the view that, in awarding costs, once a challenge is made both by way of defence and by way of attack, there is a case that has to be met. The Full Court distinguished between assertions of lack of novelty and obviousness on one hand, which could be considered discrete issues, and lack of fair basis which, may be ‘wrapped up’ in the arguments on construction. In DSI, Yates J took the view that the interplay in that case between claim infringement and claim invalidity by reason of construction was such that it was not possible to apportion costs on the basis of issues. This did not apply to manner of manufacture, sufficiency of description, best method or utility but, his Honour said, those issues occupied ‘minimal time’. These observations are apposite to this case.Costs of the appeal In our view, it is appropriate to make orders for the costs of the appeal compendiously, that is, of the patent case on infringement, the patent case on validity and the copyright infringement case. The question of construction was necessarily relevant to patent infringement and validity. We take into account that Apotex was ultimately successful in defending patent infringement but that its attack on the patent validity failed; Sanofi was successful in upholding patent validity in the face of the attack pressed in the appeal. Sanofi was successful in the copyright case but that occupied a relatively small part of the appeal.